Spike Protein News and Research

RSS

Using proteins to track SARS-CoV-2 infections through wastewater

A new study published on the preprint server medRxiv* in September 2020 describes the measurement of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) proteins in wastewater as a reliable way to track the virus in the community.

6 Sep 2020

Novel RNA vaccine from Arcturus Therapeutics protects mice against SARS-CoV-2

A new study published on the preprint server bioRxiv in September 2020 reports a novel RNA vaccine platform that shows robust protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in mice and performs much better than a conventional mRNA vaccine. This could allow single-dose immunization, allowing progress towards global vaccination.

6 Sep 2020

Study shows SARS-CoV-2 cell receptor is a novel target of the gamma-secretase enzyme complex

Based on structural similarities with other targets of the gamma-secretase system, researchers from Columbia University Irving Medical Center in the United States show that the SARS-CoV-2 receptor for cell entry may be affected by its proteolytic activity. Their results are currently freely available in a bioRxiv preprint paper.

6 Sep 2020

Antibody responses against seasonal common cold coronaviruses may protect against SARS-CoV-2

With the use of an accurate high throughput assay, researchers from the Weizmann Institute of Science and Magen David Adom Blood Services in Israel showed substantial inter-individual variability and antibody cross-reactivity against seasonal coronaviruses upon SARS-CoV-2 infection, with important implications for immune surveys and vaccines. The study is currently available on the medRxiv* preprint server.

6 Sep 2020

Early-phase Russian trials reveal safety and immunogenicity of two formulations of a two-part vaccine

Results from two early-phase Russian non-randomised vaccine trials (Sputnik V) in a total of 76 people are published today in The Lancet, finding that two formulations of a two-part vaccine have a good safety profile with no serious adverse events detected over 42 days, and induce antibody responses in all participants within 21 days.

5 Sep 2020

Study: Small neutralizing antibody can block SARS-CoV-2 from entering human cells

Researchers at Karolinska Institutet in Sweden have identified a small neutralizing antibody, a so-called nanobody, that has the capacity to block SARS-CoV-2 from entering human cells.

4 Sep 2020

Spike-based priming leads to high neutralizing activity in animal models

A new report by researchers at the University of Melbourne and published on the preprint server bioRxiv in September 2020 reports on the use of a two-protein two-dose vaccine regimen and its immunogenicity in two animal models.

4 Sep 2020

D614G spike mutation increases infectivity of SARS-CoV-2 and neutralization susceptibility

As the COVID-19 pandemic progresses, it is crucial to track the viral changes in order to link the clinical and epidemiological features of the disease with these mutations. A new study published on the preprint server bioRxiv* in September 2020 reports on a common severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mutation, D614G, and its effects on the virus.

4 Sep 2020

Research compares T cell responses to SARS-CoV-2 and influenza

As the COVID-19 pandemic continues to grow, scientists are focusing on understanding how the host immune system responds to the virus in order to better shape public health responses and develop effective vaccines. A new study published on the preprint server medRxiv in September 2020 reports the T cell memory response to the SARS-CoV-2 spike protein, recombinant nucleocapsid protein, and other pooled peptides derived from convalescent patients.

3 Sep 2020

COVID-19 vaccine candidate protects animals against SARS-CoV-2

Most people with COVID-19 have relatively mild disease, but a subset of people develop severe pneumonia and respiratory failure, potentially leading to death.

3 Sep 2020

UChicago Medicine launches clinical trial to test the potential of antibody against SARS-CoV-2

The University of Chicago Medicine is launching a clinical trial to examine the potential of an antibody against the SARS-CoV-2 spike protein for treating COVID-19, the disease caused by the novel coronavirus.

3 Sep 2020

Bioengineering technique that boosts protein production could lead to effective COVID-19 vaccine

A bioengineering technique to boost production of specific proteins could be the basis of an effective vaccine against the novel coronavirus that causes COVID-19, new research suggests.

3 Sep 2020

Study shows why coronavirus is more dangerous in people with comorbidities

Why is the COVID-19 virus more dangerous in people with comorbidities?. Sadis Matalon, Ph.D., of the University of Alabama at Birmingham and colleagues in Texas and San Francisco asked that question in a hypothesis paper published online in Physiological Reviews on March 27.

3 Sep 2020

Combined point-of-care nucleic acid and antibody testing increases COVID-19 detection

A Cambridge hospital has piloted the use of combined rapid point-of-care nucleic acid and antibody testing for SARS-CoV-2 infection after researchers at the University of Cambridge showed that this approach was superior to virus detection alone for diagnosing COVID-19 disease.

2 Sep 2020

ACE2/TMPRSS2 not expressed in pancreatic islet endocrine cells

A new study by researchers at the Vanderbilt University Medical Center and the University of Pennsylvania Perelman School of Medicine and published on the preprint server bioRxiv* in August 2020 reports that both key enzymes that are required for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) entry into the human host cell are lacking in the beta cells of the pancreatic islet. This rules out the direct injury hypothesis for impaired glucose control in patients with COVID-19 disease.

1 Sep 2020

Promising new candidate 'virus-like particle' vaccine for COVID-19

Researchers in the UK and Taiwan have demonstrated the potential of a new candidate vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the virus responsible for the current coronavirus disease 2019 (COVID-19) pandemic.

1 Sep 2020

Spike ferritin nanoparticles show potential as SARS-CoV-2 vaccine

Now, a new study published on the preprint server bioRxiv* in August 2020 reports the induction of neutralizing antibodies in mice by a single dose of a ferritin nanoparticle-based vaccine containing the spike protein.

1 Sep 2020

A nanoscaffolding approach for rapid design of highly immunogenic SARS-CoV-2 vaccines

A research group from Slovenia, Switzerland, and Germany shows how nanoscaffolded assemblies may neutralize interaction between the SARS-CoV-2 spike protein and cell receptor, providing adequate protection in a surrogate infection assay and warranting the advance of such platforms in the pursuit for the effective vaccine.

31 Aug 2020

T cell epitopes from recovered COVID-19 patients identified for vaccine

A new study by researchers at The Hong Kong University of Science and Technology and published on the preprint server bioRxiv in August 2020 collates the available database of SARS-CoV-2 T cell epitopes gathered from 8 studies of COVID-19 patients who recovered. This could serve as a launchpad to fill in knowledge gaps regarding the immunological aspects of this disease, and drive towards an effective T cell vaccine.

31 Aug 2020

Using SARS-CoV-2 epitope to construct a vaccine

A new study published on the preprint server bioRxiv* in August 2020 reports the use of prediction and advanced simulation techniques to identify a novel T cell epitope on the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that could serve as the basis for a customized vaccine with broad-based efficacy.

30 Aug 2020

Spike Protein News and Research

Using proteins to track SARS-CoV-2 infections through wastewater

Novel RNA vaccine from Arcturus Therapeutics protects mice against SARS-CoV-2

Study shows SARS-CoV-2 cell receptor is a novel target of the gamma-secretase enzyme complex

Antibody responses against seasonal common cold coronaviruses may protect against SARS-CoV-2

Early-phase Russian trials reveal safety and immunogenicity of two formulations of a two-part vaccine

Study: Small neutralizing antibody can block SARS-CoV-2 from entering human cells

Spike-based priming leads to high neutralizing activity in animal models

D614G spike mutation increases infectivity of SARS-CoV-2 and neutralization susceptibility

Research compares T cell responses to SARS-CoV-2 and influenza

COVID-19 vaccine candidate protects animals against SARS-CoV-2

UChicago Medicine launches clinical trial to test the potential of antibody against SARS-CoV-2

Bioengineering technique that boosts protein production could lead to effective COVID-19 vaccine

Study shows why coronavirus is more dangerous in people with comorbidities

Combined point-of-care nucleic acid and antibody testing increases COVID-19 detection

ACE2/TMPRSS2 not expressed in pancreatic islet endocrine cells

Promising new candidate 'virus-like particle' vaccine for COVID-19

Spike ferritin nanoparticles show potential as SARS-CoV-2 vaccine

A nanoscaffolding approach for rapid design of highly immunogenic SARS-CoV-2 vaccines

T cell epitopes from recovered COVID-19 patients identified for vaccine

Using SARS-CoV-2 epitope to construct a vaccine

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News